Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BXC1
UPID:
GP174_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BXC1; Q2M3F7
Background:
The Probable G-protein coupled receptor 174, identified by the accession number Q9BXC1, is a putative receptor for purines, which are known to play a pivotal role in cellular signaling through their interaction with G-proteins. This receptor's involvement in the intricate network of G-protein signaling pathways highlights its potential significance in various physiological processes.
Therapeutic significance:
Understanding the role of Probable G-protein coupled receptor 174 could open doors to potential therapeutic strategies. Its interaction with purines suggests a broad spectrum of biological functions, making it a compelling target for drug discovery efforts aimed at modulating G-protein coupled receptor activities.